In recent years however, a better understanding of melanoma biology and the identification of key genetic alterations causing imbalances in cell proliferation signaling (e.g., BRAF, NRAS, PTEN, CDKN2A) have revealed novel targets and therapeutic strategies for this disease (1–4). The gene discussed is PTEN; the disease is melanoma.